AVN 397
Alternative Names: AVN-397Latest Information Update: 14 Aug 2015
At a glance
- Originator Avineuro Pharmaceuticals
- Class Antidementias; Anxiolytics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Anxiety disorders
Most Recent Events
- 22 Jun 2009 Phase-II clinical trials in Alzheimer's disease in USA (unspecified route)